علاج سرطان الدم النقوي الحاد في الهجوع الأول لدى كبار السن (العمر ≥55) مع تشخيص غير ملائم

References

DOI: 10.1182/bloodadvances.2025017934

For older adults with newly diagnosed AML who have responded to initial ALT, who are candidates for an allo-HCT during first remission, and who have nonfavorable prognosis based on molecular and karyotypic characteristics, the ASH guideline panel suggests an allo-HCT over no transplantation (conditional recommendation based on very low certainty in the evidence of effects ⨁◯◯◯)

Allo-HCT may also decrease recurrence at 12 months (RR, 0.75; 95% CI, 0.56-1.01; very low certainty in evidence) and at longest follow-up (RR, 0.63; 95% CI, 0.51-0.79; 60 months follow-up; very low certainty in evidence).